Comparative in-vitro activity of ceftaroline against Staphylococcus aureus isolates from India

Bakthavatchalam, Yamuna Devi; Pragasam, Agila Kumari; Anandan, Shalini; Joshi, Sangeeta; Chaudhuri, Bhaskar Naryanan; Chitnis, DS; Roy, Indranil; Tapan, Dhole; Veeraraghavan, Balaji

doi:10.3855/jidc.7196

Cited by 5 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 Additionally, it can reach its destination quickly. 19 All of the time-kill curves for the microorganisms tested followed a similar pattern. At 8 hours, Vancomycin displayed a bactericidal effect, as indicated by a decrease in CFU/mL of more than 3 logs relative to the original number of bacteria; however, ATCC MRSA isolates continued to thrive on NA solid media.…”

Section: Discussionmentioning

confidence: 71%

Vancomycin, Linezolid, and Ceftaroline In vitro Activity Against Methicillin susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus (MRSA) Isolates

Purwoningsih¹,

Endraswari²,

Widodo³

2022

Pharmacogn J.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 71%

Vancomycin, Linezolid, and Ceftaroline In vitro Activity Against Methicillin susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus (MRSA) Isolates

Purwoningsih¹,

Endraswari²,

Widodo³

2022

Pharmacogn J.

View full text Add to dashboard Cite

show abstract

“…If the current CLSI guidelines are applied, these isolates will be classified as SDD and not as resistant. Bakthavatchalam YD et al reported a total of 13 isolates with ceftaroline MIC 2–4 µg/mL, while our study reported 14 isolates in the SDD category (2–4 µg/mL) while using CLSI 2021 criteria ( 25 ).…”

Section: Discussionmentioning

confidence: 47%

“…In January 2019, CLSI also modified the ceftaroline breakpoints and introduced the susceptible dose dependent (SDD) category for this agent, based on the recommendation by the European Medicines Agency in 2017 (High dose regimen of 600 mg every 8 h over 120 min), although this dosing regimen is not approved by the US Food and Drug Administration( 23 ). There are very few studies in India evaluating the susceptibility of S.aureus to ceftaroline and there is very little data available about the susceptibility pattern of S.aureus to ceftaroline ( 24 , 25 , 26 ). The aim of this study was to: Estimate the rate of in vitro susceptibility of ceftaroline among isolates of MRSA by E-test strip using CLSI and EUCAST breakpoints; To assess the agreement between the two guidelines for susceptibility testing of Ceftaroline; and To find the antimicrobial susceptibility pattern of MRSA isolated during the study period.…”

Section: Introductionmentioning

confidence: 99%

Ceftaroline Susceptibility among Isolates of MRSA: A Comparison of EUCAST and CLSI Breakpoints

Sachu¹

2023

Ethiop J Health Sci

View full text Add to dashboard Cite

BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) is an important bacterial pathogen causing a number of community-acquired and nosocomial infections. Ceftaroline fosamil is a fifth generation cephalosporin, approved for the treatment of infections caused by MRSA. The main objective of this study was to estimate the susceptibility of ceftaroline among isolates of MRSA by using CLSI and EUCAST breakpoints. MATERIALS AND METHODS: Fifty non-duplicate isolates of MRSA were included in the study. Ceftaroline susceptibility was done using E-strip test and interpreted using CLSI and EUCAST breakpoints. RESULTS: Susceptible isolates were equal (42%) by both CLSI and EUCAST, while resistant isolates were more commonly seen in EUCAST (50%). Ceftaroline MIC ranged from 0.25- >32μg/ml. All the isolates were sensitive to Teicoplanin and Linezolid. CONCLUSION: Resistant isolates were less (30%) while using the CLSI 2021 criteria probably due to the inclusion of SDD category. Our study showed that Fourteen isolates (28%) had Ceftaroline MIC >32μg/ml, which is an alarming finding. The high percentage of Ceftaroline resistant isolates in our study probably suggest a hospital spread of Ceftaroline resistant MRSA emphasizing the need for stringent infection control precautions.

show abstract

“…Its side effects are much lesser compared to the usual treatment regimen, i.e., glycopeptides like vancomycin and teicoplanin. Very few studies are available in world literature and in India regarding ceftaroline's susceptibility to MRSA [8][9][10]. Hence, this study was undertaken to find out the in vitro susceptibility to ceftaroline.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of In-Vitro Activity of Ceftaroline Against Methicillin-Resistant Staphylococcus aureus Clinical Isolates

Roy,

Poddar,

Panigrahi

et al. 2023

Cureus

View full text Add to dashboard Cite

Methicillin-resistant Staphylococcus aureus (MRSA) is one of the major causes of hospital and community-acquired infections. Fewer drugs, such as vancomycin, teicoplanin, and daptomycin, are effective against it, but they come with high toxicity. Fifth-generation cephalosporins like ceftaroline and second-generation cefuroxime are effective against MRSA. Limited studies are available on ceftaroline resistance in the literature. This study was undertaken to determine ceftaroline resistance in MRSA in a tertiary care hospital in Eastern India. A cross-sectional, hospital-based study was carried out with MRSA isolates obtained from various clinical samples of patients. Identification of the isolates to the species level was performed by an automated Vitek system, and selected samples were genotypically confirmed by detecting the mecA gene via real-time PCR. Out of a total of 334 Staphylococcus aureus isolates examined in this study, the prevalence of MRSA was seen in 59.3% (198/334), and methicillin-sensitive Staphylococcus aureus was in 40.7% (136/334). Of the total 198 MRSA isolates, ceftaroline intermediate MRSA was seen in 8.6% (17/198), and ceftaroline sensitive MRSA was in 91.4% (181/198), respectively. Among the 17 ceftaroline intermediate MRSA isolates, 88.2% (15/17) showed a minimum inhibitory concentration (MIC) of 2 µg/ml, and 11.8% (2/17) showed an MIC of 3 µg/ml. All the remaining 91.4% (181/198) isolates were sensitive to ceftaroline and showed an MIC ≤1 µg/ml. Real-time PCR confirmed the presence of the mecA gene in MRSA isolates. In this present study, not a single isolate was resistant to ceftaroline, suggesting that it, being a safer drug, can be used in place of glycopeptides such as vancomycin or teicoplanin and linezolid, where resistance has already been detected. The rational use of ceftaroline could be useful in clinical settings, and further studies will confirm the findings.

show abstract

Comparative in-vitro activity of ceftaroline against Staphylococcus aureus isolates from India

Abstract: This item has no abstract. Follow the links below to access the full text.

Cited by 5 publications

References 14 publications

Vancomycin, Linezolid, and Ceftaroline In vitro Activity Against Methicillin susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus (MRSA) Isolates

Vancomycin, Linezolid, and Ceftaroline In vitro Activity Against Methicillin susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus (MRSA) Isolates

Ceftaroline Susceptibility among Isolates of MRSA: A Comparison of EUCAST and CLSI Breakpoints

Evaluation of In-Vitro Activity of Ceftaroline Against Methicillin-Resistant Staphylococcus aureus Clinical Isolates

Contact Info

Product

Resources

About